Unique ID issued by UMIN | UMIN000026707 |
---|---|
Receipt number | R000030660 |
Scientific Title | Comparative efficacy and safety of anti-IL-5 therapies and placebo in patients with uncontrolled eosinophilic asthma: a meta-analysis of phase 3 trials |
Date of disclosure of the study information | 2017/03/27 |
Last modified on | 2017/03/26 16:46:04 |
Comparative efficacy and safety of anti-IL-5 therapies and placebo in patients with uncontrolled eosinophilic asthma: a meta-analysis of phase 3 trials
efficacy and safety of anti-IL-5 therapies
Comparative efficacy and safety of anti-IL-5 therapies and placebo in patients with uncontrolled eosinophilic asthma: a meta-analysis of phase 3 trials
efficacy and safety of anti-IL-5 therapies
Japan |
uncontrolled asthma
Pneumology | Adult |
Others
NO
To assess the efficacy and safety of anti-IL-5 therapies at currently recommended dosage and administration compared with placebo in patients with uncontrolled asthma
Safety,Efficacy
rate ratio for asthma exacerbation
Others,meta-analysis etc
12 | years-old | <= |
100 | years-old | > |
Male and Female
uncontrolled asthma
heavy smoker
patients with severe cardiovascular disease
1000
1st name | |
Middle name | |
Last name | koichi ando |
Showa University
Division of Respiratory Medicine and Allergology, Department of Medicine
Hatanodai, 1-5-8, Shinagawa-ku, Tokyo, Japan
+81-3784-8532
koichi-a@med.showa-u.ac.jp
1st name | |
Middle name | |
Last name | koichi ando |
Showa University
Division of Respiratory Medicine and Allergology, Department of Medicine
Hatanodai, 1-5-8, Shinagawa-ku, Tokyo, Japan
+81-3784-8532
koichi-a@med.showa-u.ac.jp
Showa University
Showa University
Other
NO
2017 | Year | 03 | Month | 27 | Day |
Unpublished
Completed
2016 | Year | 12 | Month | 28 | Day |
2016 | Year | 12 | Month | 28 | Day |
The results of present meta-analysis suggest that anti-IL-5 therapies at currently recommended dosage and administration are effective and generally well-tolerated in patients with uncontrolled eosinophilic asthma. However, the occurrence of injection site reaction warrants specific attention, especially concerning mepolizumab administration.
2017 | Year | 03 | Month | 26 | Day |
2017 | Year | 03 | Month | 26 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000030660
Research Plan | |
---|---|
Registered date | File name |
Research case data specifications | |
---|---|
Registered date | File name |
Research case data | |
---|---|
Registered date | File name |